Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Have you seen non-response to immunotherapy in locally advanced dMMR/MSI-H rectal cancer?
We describe such a case with underlying MMR heterogeneity as a potential mechanism of resistance to dostarlimab.”
Title: Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal Adenocarcinoma
Authors: Asaf Maoz, Ronald Bleday, Jeffrey Goldsmith, Shanna A. Matalon, Mark S. Redston, Molly Nestor, NP, Jonathan A. Nowak, Matthew B. Yurgelun
You can read the Full Article on JCO Precision Oncology.
More posts featuring Dostarlimab.